Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03575052 · ClinicalTrials.gov registry record · Phase 3
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
A Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 784
- Enrollment target
- 20
- Study locations
NCT03575052 is a Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 784 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT03575052, a Phase 3 study of Neuropsychiatric Symptoms Related to Neurodegenerative Disease, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 784 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pimavanserin
Study Locations (20)
Florida
- Indago Research & Health Center Inc - Hialeah
- Reliable Clinical Research, LLC - Hialeah
- Axcess Medical Research - Loxahatchee Groves
- Premier Clinical Research Institute, Inc. - Miami
- Global Medical Institutes - Miami
- Future Care Solution, LLC - Miami
- MediClear Medical & Research Center, Inc. - Miami
- Novel Clinical Research LLC - Miami
- Laszlo J Mate, MD, PA - North Palm Beach
- University of South Florida - Tampa
- Synexus Clinical Research US - The Villages
California
- ATP Clinical Research, Inc. - Costa Mesa
- Syrentis Clinical Research - Santa Ana
Arizona
- Cognitive Clinical Trials - Gilbert
Massachusetts
- Boston Center Memory - Newton
Nebraska
- Cognitive Clinical Trials LLC - Papillion
New Jersey
- The NeuroCognitive Institute - Mount Arlington
North Carolina
- UNC Hospital - Chapel Hill
Ohio
- Insight Clinical Trials LLC - Shaker Heights
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 784 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2022-05-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03575052
The ClinicalTrials.gov registry entry for NCT03575052 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 784 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropsychiatric Symptoms Related to Neurodegenerative Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03575052 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03575052 about?
NCT03575052 is a clinical study titled "A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease". The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
What is the current status of trial NCT03575052?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 784 participants. The study started on 2018-05-21. Estimated completion is 2022-05-06.
What conditions does trial NCT03575052 study?
This clinical trial studies the following conditions: Neuropsychiatric Symptoms Related to Neurodegenerative Disease.
What interventions are being tested in trial NCT03575052?
The interventions under investigation include: Placebo (DRUG), Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03575052?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03575052 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.